articleThe LancetJan 1, 2005Closed access

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Erasmus MC · Istanbul University · +4 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,163
total citations
FWCI
67.44
Percentile
100%
References
34
Citations per year

Authors

14

Topics & keywords

Keywords
  • Medicine
  • Lamivudine
  • Internal medicine
  • Pegylated interferon
  • HBeAg
  • Gastroenterology
  • Combination therapy
  • Placebo
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.